|
Genotoxicity evaluation of ten nitrosamine drug substance-related impurities using 2D and 3D HepaRG cells -Pub
|
|
0
|
96
|
July 12, 2025
|
|
CMO Nitrosamine Risk Assessment
|
|
7
|
323
|
June 27, 2025
|
|
Analytical Method Development Strategy for Controlling Two New Nitrosamine Drug Substance Related Impurities (NDSRIs) in a Pharmaceutical Drug Product for Treatment of a Rare Disease -Pub
|
|
0
|
53
|
June 25, 2025
|
|
Optimizing Pharmaceutical Formulations: Strategies for Improving Stability and Minimizing Nitrosamine Impurities-Webinar
|
|
1
|
267
|
June 20, 2025
|
|
Using N-Nitrosodiethanolamine (NDELA) and N-Nitrosopiperidine (NPIP) Transgenic Rodent Gene Mutation Data and Quantum Mechanical Modeling to Derive Potency-Based Acceptable Intakes for NDSRIs Lacking Robust Carcinogenicity Data-Pub
|
|
0
|
189
|
June 6, 2025
|
|
N-Nitroso Abemaciclib
|
|
8
|
234
|
June 4, 2025
|
|
¹⁵N-Enriched NAP Test
|
|
0
|
182
|
May 31, 2025
|
|
N-nitroso Torasemide Impurity formation and control
|
|
33
|
2311
|
May 27, 2025
|
|
Testing of N-nitroso-cinacalcet
|
|
6
|
559
|
May 25, 2025
|
|
Optimizing the detection of N-nitrosamine mutagenicity in the Ames test -Pub
|
|
17
|
674
|
May 23, 2025
|
|
N-Nitroso Spinosad Impurity-A and Impurity-D
|
|
2
|
157
|
May 21, 2025
|
|
🇲🇽 Free Lhasa México Symposia: Shaping the Future of Pharma & Regulation 🇲🇽
|
|
0
|
100
|
May 13, 2025
|
|
Understanding Aqueous Nitrosation Kinetics of 4-Substituted Piperidines To Risk Assess Pharmaceutical Processes and Products-Pub
|
|
1
|
141
|
May 6, 2025
|
|
📅 Updates on Approaches to Acceptable Intakes of Nitrosamine Drug Substance Related Impurities (NDSRIs) and Bioequivalence Assessment for Reformulated Drug Products(CRCG)
|
|
39
|
3353
|
May 2, 2025
|
|
Autonomous CPCA Web-based calculator FREE
|
|
33
|
6090
|
April 30, 2025
|
|
N-nitroso-deucravacitinib
|
|
9
|
340
|
April 29, 2025
|
|
🕵🏻 OTC Market Withdrawal of Diphenhydramine
|
|
0
|
378
|
April 24, 2025
|
|
Visualization of Categorized Compounds by CPCA
|
|
67
|
8565
|
April 24, 2025
|
|
N-nitroso-esmolol
|
|
0
|
105
|
April 22, 2025
|
|
⁉️ Duloxetine Impurity NDSRI
|
|
9
|
916
|
April 22, 2025
|
|
The quagmire with the interim limit of nitroso duloxetine
|
|
6
|
552
|
April 21, 2025
|
|
N-nitrosamide carcinogenic effect
|
|
6
|
413
|
April 21, 2025
|
|
N- nitroso mebendazole
|
|
0
|
70
|
April 13, 2025
|
|
Primary amines in formation of nitrosamine
|
|
3
|
423
|
April 10, 2025
|
|
Clobam Nitrosamine Impurity
|
|
0
|
112
|
April 8, 2025
|
|
Risk mitigation based on DP specifications
|
|
10
|
608
|
April 7, 2025
|
|
:brazil: Lhasa Brazil Symposium: Aligning Pharma & Regulatory Standards Globally :brazil:
|
|
0
|
130
|
April 3, 2025
|
|
Evaluation of the nitrosamine impurities of ACE inhibitors using computational, in vitro, and in vivo methods demonstrate no genotoxic potential -Pub
|
|
8
|
529
|
April 2, 2025
|
|
Health Canada recalled drug products
|
|
0
|
683
|
April 1, 2025
|
|
Quantitative Investigation of Nitrosamine Drug Substance-Related Impurities (NDSRIs) Under Artificial Gastric Conditions by Liquid Chromatography–Tandem Mass Spectrometry and Structure–Activity Relationship Analysis -Pub
|
|
0
|
269
|
March 24, 2025
|